Citigroup Inc Bio Atla, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Bio Atla, Inc. stock. As of the latest transaction made, Citigroup Inc holds 6,025 shares of BCAB stock, worth $3,856. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,025

Previous 6,242 3.48%

Holding current value

$3,856

Previous $8,000 25.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$1.17 - $2.05 $253 - $444	-217 Reduced 3.48%	6,025 $10,000
Q2 2024 Aug 12, 2024	SELL	$1.37 - $3.92 $2,920 - $8,357	-2,132 Reduced 25.46%	6,242 $8,000
Q1 2024 May 10, 2024	BUY	$1.88 - $3.46 $3,400 - $6,259	1,809 Added 27.56%	8,374 $28,000
Q4 2023 Feb 09, 2024	BUY	$1.27 - $3.18 $7,552 - $18,911	5,947 Added 962.3%	6,565 $16,000
Q3 2023 Nov 09, 2023	SELL	$1.7 - $3.07 $22,713 - $41,018	-13,361 Reduced 95.58%	618 $1,000
Q2 2023 Aug 10, 2023	BUY	$2.83 - $3.87 $38,069 - $52,059	13,452 Added 2552.56%	13,979 $41,000
Q1 2023 May 11, 2023	SELL	$2.3 - $8.25 $92,802 - $332,879	-40,349 Reduced 98.71%	527 $1,000
Q4 2022 Feb 09, 2023	BUY	$6.29 - $11.01 $242,089 - $423,752	38,488 Added 1611.73%	40,876 $337,000
Q3 2022 Nov 10, 2022	BUY	$2.94 - $11.87 $2,734 - $11,039	930 Added 63.79%	2,388 $18,000
Q2 2022 Aug 10, 2022	SELL	$2.13 - $5.38 $5,787 - $14,617	-2,717 Reduced 65.08%	1,458 $4,000
Q1 2022 May 12, 2022	SELL	$4.38 - $18.78 $290,915 - $1.25 Million	-66,419 Reduced 94.09%	4,175 $21,000
Q4 2021 Feb 10, 2022	BUY	$19.0 - $30.95 $830,186 - $1.35 Million	43,694 Added 162.43%	70,594 $1.39 Million
Q3 2021 Nov 10, 2021	BUY	$29.44 - $43.74 $791,936 - $1.18 Million	26,900 New	26,900 $792,000

Others Institutions Holding BCAB

# of Institutions

Shares Held

17.5M

Call Options Held

500

Put Options Held

33.5K

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $23.2M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account